Control Bionics Ltd Total Assets
Control Bionics Ltd total assets. Based on the latest financial reports, Control Bionics Ltd (CBL) holds total assets worth AU$9.05 Million AUD (≈ $6.40 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Control Bionics Ltd (CBL) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Control Bionics Ltd (2014–2025)
Total assets of Control Bionics Ltd from 2014 to 2025. This chart illustrates how Control Bionics Ltd's total assets have evolved over time, based on quarterly financial data. See Control Bionics Ltd stock price for real-time trading data and today's change.
Control Bionics Ltd - Asset Composition Analysis
Control Bionics Ltd Total Assets Breakdown (December 2025)
Control Bionics Ltd total assets breakdown as of December 2025. Control Bionics Ltd's total assets of AU$9.05 Million consist of 46.3% current assets and 53.8% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 23.0% |
| Accounts Receivable | AU$1.35 Million | 14.9% |
| Inventory | AU$451.60K | 5.0% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$3.76 Million | 41.5% |
| Goodwill | AU$752.10K | 8.3% |
Asset Composition Trend (2014–2025)
This chart illustrates how Control Bionics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Control Bionics Ltd's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Control Bionics Ltd's current assets represent 46.3% of total assets in 2025, a decrease from 53.1% in 2014.
- Cash Position: Cash and equivalents constituted 23.0% of total assets in 2025, down from 36.2% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 49.0% of total assets, an increase from 6.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 41.5% of total assets.
Control Bionics Ltd Competitors by Total Assets
Key competitors of Control Bionics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Vitrolife AB
ST:VITR
|
Sweden | Skr11.30 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
Shanghai Sanyou Medical Co Ltd
SHG:688085
|
China | CN¥2.34 Billion |
|
Zhejiang Orient Gene Biotech Co Ltd
SHG:688298
|
China | CN¥7.51 Billion |
|
Nanjing Vishee Medical Technology Co Ltd
SHG:688580
|
China | CN¥1.79 Billion |
|
TAIDOC TECHNOLOGY CORP
TW:4736
|
Taiwan | NT$13.07 Billion |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $96.98 Million |
Control Bionics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.54 | 1.24 | 11.69 |
| Quick Ratio | 1.37 | 1.08 | 11.46 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$1.47 Million | AU$619.38K | AU$12.55 Million |
Control Bionics Ltd - Advanced Valuation Insights
This section examines the relationship between Control Bionics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.16 |
| Latest Market Cap to Assets Ratio | 2.08 |
| Asset Growth Rate (YoY) | 9.9% |
| Total Assets | AU$9.05 Million |
| Market Capitalization | $18.83 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Control Bionics Ltd's assets at a significant premium (2.08x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Control Bionics Ltd's assets grew by 9.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Control Bionics Ltd (2014–2025)
The table below shows the annual total assets of Control Bionics Ltd from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | AU$9.05 Million ≈ $6.40 Million |
+9.89% |
| 2024-12-31 | AU$8.23 Million ≈ $5.83 Million |
-8.80% |
| 2023-12-31 | AU$9.03 Million ≈ $6.39 Million |
+3.81% |
| 2022-12-31 | AU$8.70 Million ≈ $6.15 Million |
-35.28% |
| 2021-12-31 | AU$13.44 Million ≈ $9.51 Million |
-26.79% |
| 2020-12-31 | AU$18.35 Million ≈ $12.99 Million |
-10.53% |
| 2019-12-31 | AU$20.51 Million ≈ $14.51 Million |
+277.82% |
| 2018-12-31 | AU$5.43 Million ≈ $3.84 Million |
-13.91% |
| 2017-12-31 | AU$6.31 Million ≈ $4.46 Million |
-99.46% |
| 2016-12-31 | AU$1.16 Billion ≈ $819.21 Million |
+65.93% |
| 2015-12-31 | AU$697.75 Million ≈ $493.71 Million |
+19.86% |
| 2014-12-31 | AU$582.12 Million ≈ $411.89 Million |
-- |
About Control Bionics Ltd
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electroni… Read more